← Eichor
Study identifier: NCT05211895 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

Condition: Non-Small Cell Lung Cancer  ·  Sponsor: AstraZeneca

PhasePhase 3
Planned participants860
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center  ·  1-877-240-9479  ·  information.center@astrazeneca.com

AstraZeneca Lung Cancer Study Locator Service  ·  1-884-432-3892  ·  az-lcsl@careboxhealth.com

Always discuss trial participation with your own doctor first.

Locations (264)

Research SiteChandler, Arizona, United StatesRecruiting
Research SitePhoenix, Arizona, United StatesSuspended
Research SiteFountain Valley, California, United StatesRecruiting
Research SiteSanta Rosa, California, United StatesRecruiting
Research SiteWashington D.C., District of Columbia, United StatesRecruiting
Research SiteJacksonville, Florida, United StatesSuspended
Research SiteOrlando, Florida, United StatesRecruiting
Research SiteSaint Augustine, Florida, United StatesRecruiting
Research SiteMacon, Georgia, United StatesSuspended
Research SiteElmhurst, Illinois, United StatesSuspended
Research SiteMaywood, Illinois, United StatesWithdrawn
Research SiteNaperville, Illinois, United StatesWithdrawn

+ 252 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05211895